Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome

NCT04371393 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT04371393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04371393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2020
Completion date
January 2, 2022
Enrollment
223 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid, mesenchymal stromal cells, remestemcel-l